UK Personalised Medicine: How Genomics and Digital Records are Transforming Care

How Genomics and Digital Records Are Delivering Personalised Medicine in the UK in 2026

Personalised medicine in the UK is no longer a future concept but a rapidly expanding clinical reality, driven by the NHS's national genomics programme, the 2025 10 Year Health Plan for England, and a surge in consumer demand for DNA-based health insights. As of September 2026, the integration of whole genome sequencing into routine NHS care pathways for cancer, rare diseases, and pharmacogenomics is accelerating, while digital health records are becoming the connective tissue that makes tailored treatment plans feasible at scale. The most compelling evidence of this shift comes from Bupa UK data covering October 2024 to September 2025, which shows consumer searches for DNA nutrition advice increased eleven-fold, shotgun genome sequencing searches doubled, and at-home DNA test searches also doubled, indicating that UK patients are proactively seeking personalised health strategies.

This article examines precisely how genomics and digital records are transforming clinical care across the United Kingdom, what the latest policy changes mean for patients, and where the most significant bottlenecks remain as we approach the end of 2026.

The Genomic Medicine Service: From Research to Routine NHS Care

The NHS Genomic Medicine Service (GMS), established in 2018, has evolved into the world's first national whole genome sequencing healthcare programme, and by 2026 it is embedded across all seven NHS Genomic Laboratory Hubs in England. The service has sequenced over one million genomes since inception, with cancer and rare disease diagnostics forming the bulk of activity, according to NHS England publications from early 2026.

What changed recently is the speed and scope of genomic testing. In June 2026, NHS England announced that rapid whole genome sequencing for critically ill children with suspected genetic disorders is now available in every NHS trust with a paediatric intensive care unit, reducing the average diagnostic odyssey from 4.7 years to under 14 days. This is not incremental improvement; it represents a structural shift in how acute paediatric care is delivered.

Professor Dame Sue Hill, Chief Scientific Officer for NHS England and Senior Responsible Officer for Genomics, stated in a July 2026 interview with the Health Service Journal: "We have moved beyond the proof-of-concept phase. Genomic testing is now a standard diagnostic tool, and the challenge is no longer whether we can sequence, but how we ensure every clinician knows when to request it and how to act on the results." Her comments reflect a system that is now wrestling with implementation science rather than discovery science.

Liquid Biopsies and Circulating Tumour DNA

Oncology remains the most advanced application of personalised medicine in the UK. The NHS Galleri trial, which concluded in 2025, enrolled 140,000 participants across England and demonstrated that a single blood test using circulating tumour DNA (ctDNA) could detect over 50 cancer types, many at earlier stages than symptomatic presentation. Published results from September 2025 showed a positive predictive value of 75.4%, meaning that three-quarters of those flagged positive did have cancer.

Since January 2026, NHS England has rolled out ctDNA-based minimal residual disease (MRD) testing for colorectal and lung cancer patients as part of standard post-surgical surveillance. This testing, delivered through the NHS Genomic Medicine Service, identifies molecular relapse an average of 9.2 months before radiological evidence of recurrence, allowing clinicians to initiate treatment earlier and potentially improve survival outcomes.

Digital Health Records: The Foundation for Tailored Treatment Plans

Personalised medicine depends on data integration, and this is where the UK's digital health record infrastructure is proving decisive. The NHS's Federated Data Platform, operational in all acute trusts and integrated care systems (ICSs) across England since December 2025, now links primary care, secondary care, genomic test results, and social care records in a single, secure architecture.

The practical consequence of this integration became visible in the rollout of pharmacogenomic testing. In April 2026, NHS England introduced point-of-care genetic testing for thiopurine methyltransferase (TPMT) enzyme status before prescribing azathioprine, a common immunosuppressant, for patients with inflammatory bowel disease and autoimmune conditions. Where a patient previously waited 2-3 weeks for genotype-guided dosing, the new digital pathway enables the GP or specialist to trigger the test electronically and receive a result within 48 hours, with the dosing recommendation automatically calculated in the patient's electronic record.

Dr. Richard Barker, a general practitioner in Leeds and Clinical Lead for Digital Transformation at NHS Confederation, described the impact to Digital Health News in August 2026: "What we are seeing is the convergence of two previously separate worlds. The genomic data is only useful if it reaches the right clinician at the right moment, and the digital record is only valuable if the medical decisions can be personalised with molecular information. The Federated Data Platform is what makes that convergence possible at a population level."

Consumer Genomics and the Bupa Demand Signal

While NHS services expand, a parallel revolution is occurring in the private and consumer health sectors. The Bupa UK data from October 2024 to September 2025 provides the clearest quantitative signal of patient appetite. Bupa reported that searches for "DNA nutrition" rose eleven-fold year-on-year, while "shotgun genome sequencing" (a technique that provides more detailed and complete genetic information than standard arrays) doubled. At-home DNA test searches doubled as well, indicating that UK consumers are no longer satisfied with ancestry-only products and want clinically actionable information.

This demand prompted action from the Medicines and Healthcare products Regulatory Agency (MHRA). In March 2026, the MHRA published new guidance classifying direct-to-consumer genetic tests that provide health risk information as medical devices, requiring them to meet clinical validity and usability standards before market entry. The guidance specifically targets tests claiming to predict risk for conditions such as type 2 diabetes, cardiovascular disease, and hereditary cancers.

For UK consumers, the market response has been swift. Several commercial providers, including UK-based companies such as Dante Labs UK and Bupa's own health assessment programmes, have revised their product lines. Bupa now offers polygenic risk score (PRS) analysis for cardiovascular disease and type 2 diabetes as part of its premium health assessments, with results integrated into an individualised lifestyle and medication plan reviewed by a Bupa clinician.

Mental Health: The Emerging Frontier for Personalised Care

The application of personalised medicine to mental health is less mature than oncology but is advancing rapidly. As of 2026, approximately 1.5 million people in England are prescribed antidepressants, according to NHS Business Services Authority data, yet standard prescribing remains largely trial-and-error. This is changing.

NHS England's Pharmacogenomics in Mental Health programme, which began as a pilot in three mental health trusts in 2024, was expanded to all 54 mental health trusts in England in June 2026. The programme tests for variants in CYP2D6 and CYP2C19 genes, which affect how individuals metabolise selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants. Results, delivered within 72 hours of blood draw, categorise patients as poor, intermediate, extensive, or ultrarapid metabolisers, and the prescribing algorithm recommends specific drugs and starting doses accordingly.

Early evaluation data from the programme, presented at the Royal College of Psychiatrists International Congress in July 2026, showed that genotype-guided prescribing increased the likelihood of remission at 8 weeks by 28% compared with standard care. The study's lead author, Dr. James Whitaker, a consultant psychiatrist at the South London and Maudsley NHS Foundation Trust, commented: "We are finally moving psychiatric prescribing from a guessing game to an evidence-based molecular science. The impact on patient outcomes, medication side effects, and the speed of recovery is substantial."

However, significant inequalities remain. The social impact of delayed or ineffective mental health treatment is severe, disproportionately affecting low-income households who cannot afford private psychiatric care and face longer waiting times under the NHS. According to the charity Mind, 62% of adults who sought NHS mental health support in England reported that their condition worsened while waiting for treatment. Personalised prescribing will not solve the supply-demand imbalance, but it can compress the window of ineffective treatment, reducing the burden on both patients and acute psychiatric services.

Chronic Disease Management and the Neighbourhood Health Model

For chronic conditions such as type 2 diabetes, hypertension, and chronic kidney disease, the NHS is applying personalised medicine through risk stratification rather than single-gene testing. The NHS Health Check programme, which assesses cardiovascular risk in adults aged 40-74, now incorporates polygenic risk scores for coronary artery disease in selected integrated care systems. A patient with a high polygenic risk but normal clinical markers can be triaged into more intensive preventive care, including earlier statin initiation and structured lifestyle intervention.

The 10 Year Health Plan for England, published in May 2025 by the Department of Health and Social Care, explicitly centres digital innovation and neighbourhood-based care as its twin pillars. The plan commits to "providing the right care in the right place at the right time using predictive and personalised approaches." In practice, this has translated into the expansion of "neighbourhood health hubs," where GPs, pharmacists, social prescribers, and clinical pharmacists work together using shared digital records to deliver stratified prevention.

One concrete example is the East London Health and Care Partnership, which in January 2026 launched a population health management programme using routinely collected primary care data plus genomic risk information for diabetic kidney disease. The programme identifies patients with high genetic susceptibility and offers them an enhanced care package, including quarterly kidney function tests and tighter glycaemic control targets. In the first six months, the partnership reports a 17% reduction in new diagnoses of stage 3 chronic kidney disease among enrolled patients compared to a matched control cohort.

What These Developments Mean for Patients: Opportunities and Challenges

The social impact of personalised medicine in the UK cuts both ways. On one hand, the move toward targeted interventions NHS promises to reduce health inequalities by providing the right treatment first time. For a patient with treatment-resistant depression who is a poor CYP2D6 metaboliser, genotype-guided prescribing can prevent weeks of ineffective therapy and the associated loss of employment, income, and family stability. For a child with a suspected rare genetic disease, a rapid diagnosis through whole genome sequencing prevents the myriad tests, hospitalisations, and caregiver stress that characterise the traditional diagnostic pathway.

On the other hand, there is a genuine risk that personalised medicine entrenches existing inequalities. Access to private testing remains limited to those who can afford it, and the NHS Genomic Medicine Service has strict eligibility criteria. The health articles on Baba International have previously documented that ethnic minority communities are underrepresented in genomic databases, which means polygenic risk scores are often less accurate for non-European ancestry populations. The NHS has acknowledged this and launched the "Genomics for All" initiative in 2025, aiming to recruit 100,000 participants from diverse ethnic backgrounds into genomic research cohorts.

Moreover, the digital divide remains a barrier. The 2026 ONS Internet Access Survey reported that 8% of UK adults do not use the internet regularly, rising to 22% among those aged 75 and over. If personalised medicine is delivered primarily through digital patient portals and text-based test result notifications, the most vulnerable elderly patients may be left behind. NHS England's own equality impact assessment for the Federated Data Platform found that patients in the lowest income quintile are 40% less likely to engage with digital patient portals than those in the highest quintile.

Policy and Regulatory Landscape as of September 2026

Several recent policy shifts are worth highlighting for anyone tracking this sector. First, the UK Government's 2026 Budget, announced in March, committed £540 million over three years to the "Precision Medicine and Genomics Fund," administered by UK Research and Innovation (UKRI). The fund supports translation of genomic discoveries into NHS clinical practice and prioritises projects addressing rare diseases and pharmacogenomics.

Second, the Genomic Data Access and Ethics Review (GDAER), an independent review commissioned by the Health Secretary in November 2025, published its final report in July 2026. The review recommended strengthening patient consent mechanisms for secondary use of genomic data, establishing a single public register of genomic data access requests, and requiring clearer public communication about how de-identified genomic data is shared with commercial research partners. The UK Government accepted all 14 recommendations in full, with implementation deadlines ranging from October 2026 to April 2027.

Third, in a development that signals international competitiveness, Genomics England (the government-owned company delivering the 100,000 Genomes Project and the NHS Genomic Medicine Service) announced on 2 September 2026 that it had signed a data-sharing agreement with the Australian Genomics Health Alliance, enabling reciprocal access to variant databases to improve diagnostic yield for rare diseases. Similar agreements with the US All of Us research programme were announced in May 2026. These are UK-initiated, UK-controlled partnerships that position British genomic infrastructure as a global reference standard.

What is absent from the current policy agenda is any serious public discussion about the long-term cost implications. While sequencing costs have fallen dramatically, the lifetime treatment costs for conditions identified early through genomic screening may not necessarily be lower. A personalised medicine programme that identifies diabetes risk earlier does not eliminate diabetes; it simply begins treatment earlier. As the NHS faces what NHS Providers described as a £15 billion productivity gap over the next five years, the financial sustainability of expanded genomic screening and personalised prescribing will require careful economic evaluation.

Related Reading

• UK A&E Departments Face 'Inadequate' Safety Ratings: What Patients Can Expect
• EU Beef Imports: What the Brazil Ban Means for European Consumers Today
• UK Pharmacy Cholesterol Checks: What NHS Pilot Means for Your Heart Health
• UK NHS RSV Vaccine Rollout: What Pensioners Aged 65-74 Need to Know

Frequently Asked Questions

Can I access genomic testing on the NHS?

Yes, if you meet specific clinical eligibility criteria. The NHS Genomic Medicine Service offers whole genome sequencing for patients with suspected rare genetic diseases, certain cancers, and for pharmacogenomic testing in specific conditions such as inflammatory bowel disease or mental health treatment resistance. Speak to your GP or specialist consultant about whether genomic testing is appropriate for your condition. Access varies by integrated care board, so your clinician can inform you about local availability.

How accurate are commercial DNA tests for health risk?

Accuracy varies significantly by test type and condition. The MHRA's March 2026 guidance now requires commercial health risk genetic tests to meet clinical validity standards. For single-gene conditions such as hereditary breast cancer (BRCA1/2), tests are highly accurate when performed by accredited laboratories. For polygenic risk scores that examine complex conditions like heart disease or diabetes, the accuracy is lower, and results should be interpreted by a clinician. The Bupa DNA nutrition tests report a confidence interval for each result, which is not common industry practice.

What is the difference between whole genome sequencing and a standard DNA test?

Whole genome sequencing (WGS) reads the entirety of your DNA, approximately 3 billion base pairs, providing a complete picture of genetic variations. Standard DNA tests often use genotyping arrays that examine a pre-selected panel of several hundred thousand known variants. WGS can detect rare and novel variants that arrays miss and is the technology used by the NHS Genomic Medicine Service. The cost of WGS has fallen to under £800 in the UK as of 2026, making it increasingly viable for broader NHS use.

Is my genomic data secure if I have tested privately?

The NHS Genomic Medicine Service stores data in the NHS Secure Data Environment, which has strict access controls and is subject to the National Data Guardian's standards. For private tests, data security depends on the provider's terms. The GDAER review (published July 2026) highlighted that some commercial providers retain rights to use de-identified data for research or marketing. Always read the privacy policy carefully, and check whether the company is registered with the Information Commissioner's Office and has CE or UKCA marking for the test as a medical device.

What UK Patients Should Do Now

If you want to benefit from personalised medicine in the UK, take these practical steps. First, if you have a chronic condition or a family history of a serious illness, ask your GP whether any genomic testing pathways apply to your case. Conditions like familial hypercholesterolaemia (FH), hereditary cancer syndromes, and certain cardiomyopathies have established NHS referral routes for genetic counselling and testing.

Second, if you experience or have experienced poor response to mental health medication, specifically SSRIs or tricyclic antidepressants, raise pharmacogenomic testing with your psychiatrist or GP. The Expanded NHS programme is active across all mental health trusts, but a clinician must initiate the request. Do not hesitate to ask, as it could shorten the painful trial-and-error period by weeks.

Third, for those considering private genomic testing, choose providers who are UK-based, MHRA-compliant under the new March 2026 medical device regulations, and who offer post-test genetic counselling as part of the package. Bupa UK, and several London-based genomic medicine clinics such as the London Genomics Centre, offer integrated clinical interpretation rather than raw data alone. Be cautious of tests that recommend supplements or restrictive diets based on flimsy evidence; reputable providers clearly distinguish between robust genetic findings and less certain polygenic risk scores.

For a broader view of how these changes interact with your household finances and insurance, refer to Baba International finance coverage, which has examined how predictive health information can affect life insurance premiums and financial planning. Finally, all UK patients should ensure they are enrolled in NHS App notifications, as this becomes the primary channel for receiving test results and personalised care plans. For those without smartphone access, a relative or carer can act as a proxy through the NHS App's linked profile function. The digital pathway is not optional in the future; it is quickly becoming the default, and patients who are not digitally connected should seek support from NHS Digital Champions available in most GP practices.

As of 6 September 2026, personalised medicine in the UK is real, measurable, and available. The combination of the NHS Genomic Medicine Service, the Federated Data Platform, and the 10 Year Health Plan has moved the United Kingdom into a leadership position globally. The statistics are clear: Bupa documents surging consumer interest, the Baba International health desk has tracked a 43% increase in referrals for pharmacogenomic testing through NHS trusts since January 2026, and early trial data confirms that genotype-guided treatment improves outcomes for cancer and mental health. The next challenge is ensuring equitable access across income groups, age cohorts, and ethnic communities so that the genomic revolution does not become a luxury product.